Emerging studies suggest that selective modulation of TNFR2 could restore immune tolerance without triggering widespread inflammation, offering a promising therapeutic strategy for SLE and other autoimmune diseases (71). Here, TNFRSF1B is linked to systemic lupus erythematosus.